NAV

Cinepazide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cinepazide
DrugBank Accession Number
DB12123
Background

Cinepazide has been used in trials studying the treatment of Ischemic Stroke.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 417.506
Monoisotopic: 417.22637111
Chemical Formula
C22H31N3O5
Synonyms
  • Cinepazide
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
IloprostIloprost may increase the hypotensive activities of Cinepazide.
Isosorbide mononitrateCinepazide may increase the vasodilatory activities of Isosorbide mononitrate.
Patent BlueThe therapeutic efficacy of Cinepazide can be decreased when used in combination with Patent Blue.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cinepazide MaleateY35B3VA60V26328-04-1XSTJTOKYCAJVMJ-GVTSEVKNSA-N

Categories

ATC Codes
C04AX27 — Cinepazide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cinnamic acids and derivatives. These are organic aromatic compounds containing a benzene and a carboxylic acid group (or a derivative thereof) forming 3-phenylprop-2-enoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Not Available
Direct Parent
Cinnamic acids and derivatives
Alternative Parents
Alpha amino acids and derivatives / N-piperazineacetamides / Anisoles / Styrenes / Phenoxy compounds / Methoxybenzenes / N-acylpyrrolidines / Alkyl aryl ethers / N-alkylpiperazines / Tertiary carboxylic acid amides
show 6 more
Substituents
1,4-diazinane / Alkyl aryl ether / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
67Y4P5C84X
CAS number
23887-46-9
InChI Key
RCUDFXMNPQNBDU-VOTSOKGWSA-N
InChI
InChI=1S/C22H31N3O5/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24/h6-7,14-15H,4-5,8-13,16H2,1-3H3/b7-6+
IUPAC Name
(2E)-1-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
SMILES
COC1=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=CC(OC)=C1OC

References

General References
Not Available
PubChem Compound
5282459
PubChem Substance
347828422
ChemSpider
4445611
ChEBI
135676
ChEMBL
CHEMBL1874750
ZINC
ZINC000036379005
Wikipedia
Cinepazide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Ischemic Stroke1
2Unknown StatusTreatmentIschemic Stroke1
Not AvailableCompletedTreatmentIschemic Stroke1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.502 mg/mLALOGPS
logP1.67ALOGPS
logP0.67Chemaxon
logS-2.9ALOGPS
pKa (Strongest Basic)5.91Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area71.55 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity115.36 m3·mol-1Chemaxon
Polarizability46.39 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0005900000-83c06e16463a17008bd5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kb-3831900000-3e426c08b0574e9094c7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-4114900000-65b1bd04952b67cb2d05
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0g30-0409300000-78e124930a70cde7d121
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0100-3958300000-1548a008da6513a47de7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-05dr-0729000000-7e168e734ce2865469f5
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-199.15413
predicted
DeepCCS 1.0 (2019)
[M+H]+201.51213
predicted
DeepCCS 1.0 (2019)
[M+Na]+208.31227
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:23 / Updated at February 21, 2021 18:53